Literature DB >> 8169003

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

H C Wu1, J T Hsieh, M E Gleave, N M Brown, S Pathak, L W Chung.   

Abstract

A model of human prostate cancer was established to study cellular interaction between prostate cancer and bone stroma in vivo. In this model, subcutaneous co-injection of 2 non-tumorigenic human cell lines--LNCaP, a prostate cancer cell line, and MS, a bone stromal cell-line--into intact adult male mice resulted in formation of carcinomas that secreted prostate-specific antigen (PSA), a clinically useful human serum prostate cancer marker. In castrated hosts, upon cellular interaction with bone fibroblasts, we observed the progression of these tumors from an androgen-dependent (AD) to an androgen-independent state (AI). We derived 4 LNCaP cell sublines from the chimeric LNCaP/MS tumors: the M subline from intact hosts and the C4, C4-2 and C5 sublines from castrated hosts. The LNCaP sublines had chromosomal markers similar to those of the parental LNCaP cells and distinctly different from those of the MS bone stromal cell line. Although the parental and derived cell lines expressed similar steady-state levels of ornithine decarboxylase transcript, the sublines expressed 5- to 10-fold higher basal steady-state levels of PSA transcript than did the parental LNCaP cell line. The LNCaP sublines formed 13- to 26-fold more soft-agar colonies than the parental LNCaP cell line. The sublines became tumorigenic, yielding an incidence of tumors in intact athymic mice of 7-75%. The LNCaP sublines C4 and C5 (but not the parental and M cell line) formed tumors in castrated hosts when co-injected with bone fibroblasts. A second-generation LNCaP subline, C4-2, was derived from a chimeric tumor induced by co-inoculating castrated mouse with C4 cells and MS cells. We found that C4-2 subline was tumorigenic when inoculated into castrated hosts in the absence of inductive fibroblasts. Moreover, C4-2 was the only subline capable of forming soft-agar colonies when cultured in serum-free medium. In comparison with the parental LNCaP cells, the C4-2 subline expressed lower steady-state levels of androgen receptor (AR) protein and mRNA transcript and lost its androgen responsiveness in vitro. Our results suggest that certain genetic traits of prostate cancer cells may be selected or altered through an "adaptive" mechanism that involves cellular interaction with the bone stromal cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169003     DOI: 10.1002/ijc.2910570319

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  187 in total

1.  Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Authors:  Yue Wu; Li Tang; Gissou Azabdaftari; Elena Pop; Gary J Smith
Journal:  Mol Cell Endocrinol       Date:  2019-02-23       Impact factor: 4.102

2.  Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.

Authors:  Puranik Purushottamachar; Andrew K Kwegyir-Afful; Marlena S Martin; Vidya P Ramamurthy; Senthilmurugan Ramalingam; Vincent C O Njar
Journal:  ACS Med Chem Lett       Date:  2016-05-23       Impact factor: 4.345

Review 3.  The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Authors:  Benjamin A Mooso; Ruth L Vinall; Maria Mudryj; Stanley A Yap; Ralph W deVere White; Paramita M Ghosh
Journal:  J Urol       Date:  2014-08-23       Impact factor: 7.450

4.  The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.

Authors:  Smita Awasthi; Heather Ezelle; Bret A Hassel; Anne W Hamburger
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

5.  A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.

Authors:  Lauren Brady; Rui M Gil da Costa; Ilsa M Coleman; Clinton K Matson; Michael C Risk; Roger T Coleman; Peter S Nelson
Journal:  Prostate       Date:  2020-02-18       Impact factor: 4.104

6.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 7.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

9.  Parathyroid hormone-related protein regulates integrin α6 and β4 levels via transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V R Mula; Miriam Falzon
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

10.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.